Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Deal with NHI Drug Prices before Medical Fees: Mr Kawasaki
December 12, 2005
- Healthcare Reform Framework Announced
December 12, 2005
- Toho: Profits Decline 39.3% Despite 24.6% Growth in Sales
December 5, 2005
- PhRMA Disappointed by Chuikyo's NHI Pricing Reform Proposal
December 5, 2005
- Mediceo Paltac Approves Merger of Paltac and Alcos in April 2006
December 5, 2005
- FJPWA Seminar on Management of Wholesalers
December 5, 2005
- Mediceo Paltac to Take Pricing Power Back to Headquarters: Mr Kumakura
December 5, 2005
- Survey Finds Growing Gap Between Market Prices and NHI Prices
December 5, 2005
- Mediceo HD: Profits Down Despite Growth in Sales
December 5, 2005
- Operating Profit Ratios Hold Steady for 4 Leading Wholesalers
December 5, 2005
- Bayer to Increase Investment in Asia-Pacific
December 5, 2005
- REGULATORY NEWS IN BRIEF
December 5, 2005
- R&D NEWS IN BRIEF
December 5, 2005
- Clopidogrel, Silodosin Recommended for Approval
December 5, 2005
- MEDICAL DEVICE NEWS IN BRIEF
December 5, 2005
- Chuikyo Recommends Approval of 4 Ingredients/6 Products
December 5, 2005
- New Medical Materials Should Be Listed 4 Times a Year: Device Industry
December 5, 2005
- Committee Approves Basic Proposal for Next Revision of Med. Fees
December 5, 2005
- 58% of Pharmacists Have Been Asked to Dispense Generics: Survey
December 5, 2005
- Approval of 3 New Products Recommended
December 5, 2005
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…